Resources

Publications

 

 

Show All

March 2011

Anson BD, Kolaja KL, and Kamp TJ

Opportunities for Use of Human iPS Cells in Predictive Toxicology

Clin Pharmacol Ther 89(5):754-758

Publication Date: March 23, 2011

Product Type: CDI Technology

Summary:

Description of the properties of human induced pluripotent stem (iPS) cells that make them a promising source for toxicity assessment, highlight the progress to date, and point out the important roadblocks that remain.

Howden SE, Gore A, Li Z, Fung HL, Nisler BS, Nie J, Chen G, McIntosh BE, Gulbranson DR, Diol NR, Taapken SM, Vereide DT, Montgomery KD, Zhang K, Gamm DM, and Thomson JA

Genetic Correction and Analysis of Induced Pluripotent Stem Cells from a Patient with Gyrate Atrophy

Proc Natl Acad Sci USA 108(16):6537-6542

Publication Date: March 1, 2011

Product Type: CDI Technology

Summary:

Isolation of iPS cells free of transgene sequences from a patient with gyrate atrophy caused by a point mutation in the gene encoding ornithine-δ-aminotransferase (OAT) and use of homologous recombination to correct the genetic defect.

Yu J, Chau KF, Vodyanik MA, Jiang J, and Jiang Y

Efficient Feeder-free Episomal Reprogramming with Small Molecules

PLoS One 6(3):e17557

Publication Date: March 1, 2011

Product Type: CDI Technology

Summary:

Establishment of a feeder-free reprogramming condition using chemically defined medium with bFGF and N2B27 supplements and chemically defined human ESC medium mTeSR1 for the derivation of footprint-free human iPSCs.